Incremental Cost-Effectiveness ICERs, Quadrants, CEAC, INB, EVPI (Many of the followng calculations use Central Limit Theorem formula based on studies by Nixon et al.) Calculator and Plotter |

Different Types of Potential Results :::

(Beta Test Version - for educational experimentation only, not for official use)

Nine DATASETS (Click "A" to "I") | Effect Difference Vs Baseline |
|||

Lower | Equal | Higher | ||

Cost Difference Vs Baseline |
Higher | A | B | C |

Equal | D | E | F | |

Lower | G | H | I | |

A = Dominated (higher cost and less effective vs baseline).

C= Tradeoff (higher cost and more effective vs baseline).

E = Arbitrary (similar cost and similar effect vs baseline).

G = Tradeoff (lower cost and lower effectiveness vs baseline).

I = Dominant (lower cost and more effective vs baseline).

Sample Chart from Results Pages

Incremental Quadrant Explanation

**
**

Resources:

1.
Kerelakes DJ, Obenchain RL et al. Abciximab provides cost-effective survival
advantage in high-volume interventional practice. Am. Heart J. 140:603-10;**
2000**.

2.
Obenchain RL. Resampling and multiplicity in cost-effectiveness inference.
J. Biopharmaecutical Statistics. 9(4), 563-582, 1999.

3.
Obenchain RL et al. Bootstrap analyses of cost effectiveness in antidepressant
pharmacotherapy. PharmacoEconomics. 11(5):464-472, 1997.

4.
**Briggs
AH, O’Brien BJ, and Blackhouse G.** **Thinking
Outside the Box: Recent Advances in the Analysis and Presentation of Uncertainty
in Cost-Effectiveness Studies**. Annual Rev. Public Health.
23:377–401, 2002.

5.
Nixon RM et al. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
Health Economics. 19:316-333, 2010.

6.
Kim N. et al. An economic analysis of usual care and acupuncture collaborative treatment on chronic low back pain: a Markov decision analysis.
BMC Complementary and Alternative Med. 10:74, 2010.